Talking on their SEZ sale plans he said they would wait for the Budget before deciding on it, said Arpit Vyas, MD, Dishman Pharma.

Margins to pick up in H2, will meet FY15 guidance: Dishman

Dishman Pharma‘s margins were down due to stock building but they are expected to pick up in the second half of this fiscal, says company MD Arpit Vyas.

Dishman pins hopes on China unit

JR Vyas, MD, Dishman Pharma says Carbogen Amcis anticipates a turnover of 96 million this fiscal and a turnover of 106 million the next fiscal year.

Dishman Pharma post standalone Q2 PAT at Rs 13.52cr sans Fx

Arpit Vyas, MD of Dishman Pharma presents his views on the company‘s quarterly earnings, in an interview to CNBC-TV18.

Pharma cos likely to post 21% EBITDA growth in Q4: MOST

Motilal Oswal has come with its March`13 quarterly earning estimates for healthcare sector. The research firm expects a top line growth of 17.4% YoY and EBITDA growth of 21.3% YoY for our pharma universe (excluding one-offs).

See pharma sector's Q3 topline to grow 22%: Motilal Oswal

Motilal Oswal has come out with its earnings estimates for pharmaceuticals sector for the quarter ended December 2012. The research firm expects the topline to grow by 22 percent, EBITDA by 21 percent on the back of strong operational performance by Ranbaxy, Glenmark, Strides, Torrent and Divi's.

See pharma sector's margins to dip 314 bps in 3QFY13: Angel

Angel Broking has come out with earning expectations for pharmaceutical sector for the October-December quarter of 2012. The research firm expects the Indian pharma sector to post lackluster numbers for 3QFY2013 on the sales front.

Contract research to boost performance in FY13: Dishman

In an interview with CNBC-TV18, JR Vyas, MD of Dishman Pharma said the the contract research income is going to boost the company's performance through FY13.

Dishman Pharma expects 25% growth in FY13

Dishman Pharmaceuticals posted a 13.24% topline growth in the fourth quarter of FY12 and reported a consolidated net profit of Rs 312.94 million for the quarter ended 31 March, 2012, up 37.30% from Rs 227.92 million in the corresponding quarter last year.

See strong performance by pharma in Mar quarter: KR Choksey

According to the report on earnings preview for the quarter ended March 2012, KR Choksey expects the pharma sector will show strong performance in the domestic pharmaceuticals market mainly due to recovery in Indian pharma market.

Better R&D income led to jump in profits: Dishman Pharma

Managing director of Dishman Pharma tells CNBC-TV18 that higher earnings from its contract revenue business is what led to the surge in third quarter profits.

Pharma Q3: New launches, generic drug demand to aid growth

Pharmaceutical companies are expected to report healthy 15-25% year-on-year revenue growth in the third quarter, helped by new launches especially in the US and strong demand for generic drugs.

Pharma stocks results preview for Q3FY12: KRChoksey

KRChoksey has come with its December quarterly earning estimates for Pharma sector. According to the research firm, Q3FY12 is expected to be a strong quarter in terms of top-line growth mainly due to improved performance in the Indian pharmaceutical market, launch of limited competitive products in the US market & rupee depreciation.

Pharmaceutical results preview for Q3FY12: Emkay

Emkay Global Financial Services has come with its December quarterly earning estimates for pharmaceutical sector. According to the research firm the sector is expected to report a growth of 18% YoY (5% QoQ) in revenues partly driven by Rupee depreciation which is likely to be 4-5% of the overall growth.

Dishman Pharma eyes over 15% topline growth going forward

Managing director of Dishman Pharmaceuticals, JR Vyas expects the topline growth to be 15% or even more going forward. He also added that the bottomline will grow in the second half too.

Dishman Sept qtr PAT seen down 50% at Rs 15 cr: KR Choksey

KR Choksey has come out with its earning estimates on Pharma sector for the quarter ended September 2011. According to the research firm, Dishman Pharma September quarter net sales are expected to go up by 9% at Rs 254 crore, year-on-year, (YoY) basis.

Dishman Sept qtr PAT seen up 21% at Rs 10cr: Dolat Capital

Dolat Capital has come out with its earning estimates on Pharma sector for the quarter ended September 2011. According to the research firm, Dishman September quarter net sales are expected to go up by 15.1% at Rs 245 crore, year-on-year, (YoY) basis.

Dishman Pharma Mar qtr PAT seen down at Rs 2.3 cr: MOST

Motilal Oswal has come out with its earning estimates on Pharmaceuticals sector for the quarter ended March 2011. According to the research firm, Dishman Pharma March quarter sales are expected to go down by 5.6% at Rs 233.9 crore, year-on-year, (YoY) basis.

Dishman Pharma March qtr PAT seen at Rs 3cr: KRChoksey

KRChoksey has come out with its earning estimates on pharma sector for the quarter ended March 2011. According to the research firm, Dishman Pharmaceuticals & Chemicals March quarter sales are expected to go down by 3% at Rs 240 crore, year-on-year, (YoY) basis.

Q4 to be better compared to Q3: Dishman Pharma

Dishman Pharma has reported a consolidated net profit of Rs 1.7 crore for the quarter ended December 2010 as against Rs 33 crore in same quarter, the previous year. The company's consolidated net sales increased to Rs 230 crore from Rs 220 crore (YoY).

Dishman Pharma Dec qtr PAT seen up 11% at Rs 36.7cr: Angel

Angel Broking has come out with its earning estimates on the pharmaceutical sector for the quarter ended December 2010. According to the research firm, Dishman Pharma December quarter net sales are expected to go up by 30.9% to Rs 291 crore, Year-on-Year, (Y-o-Y) basis.

Dishman Pharma Dec qtr PAT seen down 47% at Rs 17cr: Karvy

Karvy Stock Broking has come out with its earning estimates on pharma sector for the quarter ended December 2010. According to the research firm, Dishman Pharmaceuticals December quarter sales are expected to go up by 5.3% at Rs 235.3 crore, Year-on-Year, (YoY) basis.

Dishman Pharma Dec qtr PAT seen up 3% at Rs 34cr: KRChoksey

KRChoksey has come out with its earning estimates on pharma sector for the quarter ended December 2010. According to the research firm, Dishman Pharmaceuticals & Chemicals December quarter sales are expected to go up by 25% to Rs 277 crore, Year-on-Year, (Y-o-Y) basis.